公开(公告)号：EP4187246A1

公开(公告)日：2023-05-31

申请号：EP21847073.0

申请日：2021-07-20

Applicant: FUJIFILM Corporation ,  Osaka University

Inventor： MIYOSHI, Eiji ,  MORISHITA, Koichi ,  SHINZAKI, Shinichiro ,  MOTOOKA, Kei ,  KIDOWAKI, Kayoko ,  TAMURA, Ikumi ,  DATE, Mutsuhiro

IPC: G01N33/53 ,  C12M1/34

Abstract: An object of the present invention is to provide a method of assisting diagnosis of inflammatory bowel disease, which can specifically determine inflammatory bowel disease.
The present invention relates to "a method of assisting diagnosis of inflammatory bowel disease, the method including subjecting a subject-derived specimen to a reduction treatment and subsequently measuring a human prohaptoglobin amount in the specimen by using an antibody 1 which is an antibody that specifically binds to an amino acid sequence set forth in SEQ ID NO: 1, and determining that a subject has inflammatory bowel disease by using the human prohaptoglobin amount as an indicator, and relates to an examination kit for assisting diagnosis of inflammatory bowel disease, including the antibody 1 a reducing agent".

公开(公告)号：EP4169941A1

公开(公告)日：2023-04-26

申请号：EP21829606.9

申请日：2021-06-22

Applicant: Mitsui Chemicals, Inc. ,  OSAKA UNIVERSITY ,  University of Miyazaki

Inventor： ISHIKAWA, Komako ,  AMANO, Koh ,  TAKAO, Toshifumi ,  OKUMURA, Nobuaki ,  TAKEI, Toshiki ,  NAKAZATO, Masamitsu ,  TSUBOUCHI, Hironobu

IPC: C07K16/18 ,  G01N33/574 ,  G01N33/70

Abstract: An ELISA method having an excellent high throughput property, wherein adenocarcinoma is efficiently detected with high sensitivity and specificity. An adenocarcinoma detection method based on a protein fragment of WFDC2 protein in a sample originating from a subject, the method comprising determining a presence of adenocarcinoma by comparing a first determination value and a threshold value set in advance, the first determination value being a value derived by dividing a first fragment quantity, which is a quantity of a protein fragment having an amino acid sequence of SEQ ID NO: 1 in the sample as determined by an ELISA method, by a reference quantity defined by a total quantity of WFDC2 protein or a creatinine concentration in the sample as determined by an ELISA method.

公开(公告)号：EP4166683A1

公开(公告)日：2023-04-19

申请号：EP21823044.9

申请日：2021-05-26

Applicant: OSAKA UNIVERSITY

Inventor： NAKANO, Takayoshi ,  NAGASE, Takeshi ,  MATSUGAKI, Aira

IPC: C22C14/00 ,  C22C16/00 ,  C22C27/02 ,  C22C27/04 ,  C22C28/00 ,  C22C30/00 ,  C22C1/02 ,  C22F1/00 ,  C22F1/16 ,  C22F1/18 ,  A61L27/04 ,  A61L27/06 ,  B33Y70/10 ,  B22F3/105 ,  B22F3/16

Abstract: An object of the present invention is to provide a multi-component system alloy having high strength and high ductility.
A multi-component system alloy is characterized by containing titanium, zirconium, niobium, molybdenum, and tantalum, and further the multi-component system alloy containing at least one selected from the group consisting of hafnium, tungsten, vanadium, and chromium, wherein the alloy satisfies Mo equivalent ≧ 13.5, and the alloy is a single-phase solid solution, a two-phase solid solution, or an alloy in which main phase is a solid solution phase. Furthermore, in a preferred embodiment of the multi-component system alloy of the present invention, it is characterized in that the alloy contains titanium, zirconium, niobium, molybdenum, tantalum, and hafnium.

公开(公告)号：EP4163870A1

公开(公告)日：2023-04-12

申请号：EP22186449.9

申请日：2022-07-22

Applicant: TOPCON CORPORATION ,  Osaka University

Inventor： NISHIDA, Kohji ,  MIKI, Atsuya ,  MARUYAMA, Kazuichi ,  KAWASAKI, Ryo ,  MEI, Song ,  MAO, Zaixing ,  WANG, Zhenguo ,  CHAN, Kinpui ,  SUI, Xin

IPC: G06T7/00 ,  G06T7/12 ,  G06T7/62

Abstract: A medical diagnostic apparatus includes a receiver circuit that receives three-dimensional data of a subject's eye, and a processor configured to separate portions of the three-dimensional data into separate segments, perform processing differently on each of the separate segments, and combine the separately processed segments to produce a segmented three-dimensional data set. The processor is further configured to generate at least one diagnostic metric from the segmented three-dimensional data set, and the processor is further configured to evaluate a pathological condition based on the at least one diagnostic metric. Related methods and computer readable media are also disclosed.

公开(公告)号：EP4154877A1

公开(公告)日：2023-03-29

申请号：EP21809755.8

申请日：2021-03-05

Applicant: OSAKA UNIVERSITY

Inventor： HIRANO Ken-ichi

IPC: A61K31/23 ,  A23L2/52 ,  A23L33/10 ,  A23L33/115 ,  A61P9/00 ,  A61P9/10

Abstract: The present invention provides an agent for inducing regression of triglyceride (TG) deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, an agent for improving blood flow in a patient with TG deposit atherosclerosis, which agent comprises tricaprin/trisdecanoin as an active ingredient, and a pharmaceutical or food or drink product comprising the agent for inducing regression of TG deposit atherosclerosis or the agent for improving blood flow.

公开(公告)号：EP4151198A1

公开(公告)日：2023-03-22

申请号：EP21804042.6

申请日：2021-05-14

Applicant: OSAKA UNIVERSITY

Inventor： KATO Hiroki ,  FUKASE Koichi ,  KABAYAMA Kazuya ,  SHIMOYAMA Atsushi ,  KADONAGA Yuichiro ,  TOYOSHIMA Atsushi ,  SHINOHARA Atsushi ,  KANEDA Yasufumi ,  NISHIKAWA Tomoyuki

IPC: A61K20060101

Abstract: The present invention relates to a gold nanoparticle-containing medicine, and a treatment of a proliferative disease using the medicine. The present invention also relates to a gold nanoparticle-containing medicine that is bound to an alpha radioactive nucleus, and a treatment of a proliferative disease using the medicine.

公开(公告)号：EP4141884A1

公开(公告)日：2023-03-01

申请号：EP21792328.3

申请日：2021-04-22

Applicant: OSAKA UNIVERSITY

Inventor： ASANOI, Hidetsugu ,  SAWA, Yoshiki ,  MIYAGAWA, Shigeru ,  IKEGAWA, Sunao

IPC: G16H50/20

Abstract: This invention relates to a prediction support system 1 for supporting prediction of the severity of a disease, comprising:
a detection device 2 for continuously detecting whether a patient with the disease is in bed,
an acquisition unit 33 for acquiring, based on the detection result of the detection device 2, an in-bed pattern D1 indicating, as a time series, whether the patient is in bed.

公开(公告)号：EP4095245A1

公开(公告)日：2022-11-30

申请号：EP21744534.5

申请日：2021-01-25

Applicant: C4U Corporation ,  OSAKA UNIVERSITY

Inventor： MASHIMO, Tomoji ,  YOSHIMI, Kazuto ,  SHIBUMURA, Satomi

IPC: C12N15/09 ,  C12Q1/68

Abstract: It has been found that by mixing a single-stranded probe DNA whose cleavage can be detected in a reaction system containing a CRISPR-Cas3 system and a sample from which to detect a target DNA, it is possible to detect the target DNA in the sample by using, as indication, a signal generated by the cleavage of the single-stranded probe DNA.

公开(公告)号：EP4063845A1

公开(公告)日：2022-09-28

申请号：EP20890874.9

申请日：2020-11-13

Applicant: OSAKA UNIVERSITY ,  Tosoh Corporation

Inventor： UEMURA, Motohide ,  NONOMURA, Norio ,  UJIKE Takeshi ,  MYOBA, Shohei ,  OHTAKE, Norihisa

IPC: G01N27/62 ,  G01N33/53 ,  G01N33/574 ,  G01N33/68

Abstract: A problem to be addressed by the present invention is to provide: a method for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) in a simple and highly accurate manner; and a reagent that can be used in the method. Bone metastasis of cancer (excluding castration resistant prostate cancer) is detected by measuring an intact growth and differentiation factor 15 (GDF15) propeptide level, a GDF15 propeptide fragment level, and the total of an intact GDF15 propeptide level and a GDF15 propeptide fragment level in a sample. The above described method for detecting bone metastasis of cancer includes a method for detecting bone metastasis of prostate cancer other than castration resistant prostate cancer, renal cancer, lung cancer, breast cancer, thyroid cancer, pancreatic cancer, bladder cancer, colon cancer, melanoma, myeloma, or lymphoma. Further, the reagent for detecting bone metastasis of cancer (excluding castration resistant prostate cancer) includes an antibody that specifically recognizes GDF15 propeptide.

公开(公告)号：EP4059523A1

公开(公告)日：2022-09-21

申请号：EP20887181.4

申请日：2020-11-12

Applicant: OSAKA UNIVERSITY

Inventor： TAKASHIMA, Seiji ,  MATSUOKA, Ken ,  ASANO, Yoshihiro ,  TSUKAMOTO, Osamu ,  KIOKA, Hidetaka

IPC: A61K48/00 ,  A61P9/04 ,  C12N15/12 ,  C12N15/63 ,  A61K35/76

Abstract: The object of the present invention is to provide a polynucleotide which can be inserted into an expression vector and can enhance the transcriptional activity of a predetermined promoter under heart failure.
The object is achieved by an enhancer polynucleotide comprising a polynucleotide consisting of a sequence having 80% or more identity with a sequence represented by SEQ ID NO: 1, or a polynucleotide consisting of a sequence having 80% or more identity with a sequence represented by SEQ ID NO: 2, wherein the enhancer polynucleotide responds to heart failure (where the enhancer polynucleotide excludes a polynucleotide having the same sequence as a sequence represented by SEQ ID NO: 13 and a polynucleotide having the same sequence as a sequence represented by SEQ ID NO: 12).